418 related articles for article (PubMed ID: 26065656)
21. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
Molica S
Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
[TBL] [Abstract][Full Text] [Related]
22. Prognostic markers and standard management of chronic lymphocytic leukemia.
Stilgenbauer S
Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
[TBL] [Abstract][Full Text] [Related]
23. Initial therapy of chronic lymphocytic leukemia.
Eichhorst B; Cramer P; Hallek M
Semin Oncol; 2016 Apr; 43(2):241-50. PubMed ID: 27040702
[TBL] [Abstract][Full Text] [Related]
24. Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Network Meta-analysis.
Davids MS; Waweru C; Le Nouveau P; Padhiar A; Singh G; Abhyankar S; Leblond V
Clin Ther; 2020 Oct; 42(10):1955-1974.e15. PubMed ID: 33032842
[TBL] [Abstract][Full Text] [Related]
25. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach?
Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S
Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408
[TBL] [Abstract][Full Text] [Related]
26. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Wendtner CM; Gregor M
Leuk Lymphoma; 2018 Feb; 59(2):300-310. PubMed ID: 28565930
[TBL] [Abstract][Full Text] [Related]
27. Past, present and future role of chlorambucil in the treatment of chronic lymphocytic leukemia.
Goede V; Eichhorst B; Fischer K; Wendtner CM; Hallek M
Leuk Lymphoma; 2015 Jun; 56(6):1585-92. PubMed ID: 25219593
[TBL] [Abstract][Full Text] [Related]
28. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
29. What Is the Role of Chemotherapy in Patients With Chronic Lymphocytic Leukemia?
Cheson BD
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):723-727. PubMed ID: 28780145
[TBL] [Abstract][Full Text] [Related]
30. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
32. Impact of novel agents on patient-relevant outcomes in patients with previously untreated chronic lymphocytic leukemia who are not eligible for fludarabine-based therapy.
Singh M; Mealing S; Baculea S; Cote S; Whelan J
J Med Econ; 2017 Oct; 20(10):1066-1073. PubMed ID: 28720054
[TBL] [Abstract][Full Text] [Related]
33. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
Cramer P; Isfort S; Bahlo J; Stilgenbauer S; Döhner H; Bergmann M; Stauch M; Kneba M; Lange E; Langerbeins P; Pflug N; Kovacs G; Goede V; Fink AM; Elter T; Fischer K; Wendtner CM; Hallek M; Eichhorst B
Haematologica; 2015 Nov; 100(11):1451-9. PubMed ID: 26315931
[TBL] [Abstract][Full Text] [Related]
34. Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Seiter K; Mamorska-Dyga A
Clin Interv Aging; 2015; 10():951-61. PubMed ID: 26109852
[TBL] [Abstract][Full Text] [Related]
35. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
36. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
Huang Q; Deering KL; Harshaw Q; Leslie LA
Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
[TBL] [Abstract][Full Text] [Related]
37. Ofatumumab in the treatment of chronic lymphocytic leukemia.
Tsimberidou AM
Drugs Today (Barc); 2010 Jul; 46(7):451-61. PubMed ID: 20683500
[TBL] [Abstract][Full Text] [Related]
38. Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia.
Khan Y; Lyou Y; El-Masry M; O'Brien S
Expert Rev Hematol; 2020 Jan; 13(1):31-38. PubMed ID: 31756301
[No Abstract] [Full Text] [Related]
39. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
40. Chronic lymphocytic leukemia (CLL)-Then and now.
Rai KR; Jain P
Am J Hematol; 2016 Mar; 91(3):330-40. PubMed ID: 26690614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]